Background: BKPyV is an important cause of premature graft failure after KT. Most
| INTRODUC TI ON
Infections are important complications after KT in children. BKPyV has emerged as significant pathogen in this setting, as it may cause severe nephritis, PyVAN, and graft loss. 1 Primary BKPyV infection occurs during childhood, mostly as a subclinical infection. Over 80% of the children and adolescents are seropositive for BKPyV. 2, 3 After the primary infection, BKPyV persists latent in the epithelial cells of the renourinary tract with sporadic low-level replication. 2 The decrease in immune control, however, leads to significant increases in urinary BKPyV loads, which may progress in KT recipients to extensive cytopathic tubular damage, inflammation, tubular atrophy, and interstitial fibrosis.
Pediatric KT recipients are at the increased risk of primary infection through the transplanted organ as well as normal community transmission with potentially dire consequences for the graft. 4, 5 High-level BK viruria is typically the first step defined by the appearance of urinary "decoy cells" and/or urine viral loads of more than 7 log10 copies/mL in 20%-40% of adult KT patients, but
higher rates have been reported in pediatric populations. Within 4-8 weeks, up to one half of these patients progress to BK viremia.
BKPyV viremia has been shown to be derived almost exclusively from the renal allograft. 6, 7 Without any intervention, at least half of the patients progress to histologically proven BKPyV nephropathy with the next 6 weeks. 8 These cases often present with more extensive and advanced disease, having plasma BKPyV load significantly above 10 000 copies/mL. Due to the focal nature of BKPyV replication in the renal allograft, early stages of the disease may have false-negative biopsies in 10%-30% of the cases. 9,10 Screening for high-level BK viruria and viremia permits the judicious reduction in IS to enable BKPyV-specific T cells to clear replication foci and prevent from destructive nephropathy. 12 Currently, the reduction in IS is the main practice to improve immunity against BKPyV. 13, 14 Notably, a recent report of Sawinski et al 15 suggests that persistent BK viremia associates with increased risk of DSAs, similar to the other viruses (CMV and EBV) that may mediate allosensitization.
In addition to BKPyV viruria and viremia, serology has been proposed as an additional tool to identify patients at increased risk of post-transplant infections. 16, 17 Negative serostatus increases the risk of PyVAN in pediatric recipients. 5, 19 However, data on the effect of BKPyV replication on long-term graft function in pediatric KT recipients are scarce. In this study, we aimed at characterizing the incidence of post-transplant BKPyV viremia and long-term graft function in pediatric KT recipients and investigating the potential role of the BKPyV-specific antibodies. 
| PATIENTS AND ME THODS

| Patients
| RE SULTS
| Baseline characteristics
| Pre-and post-transplant BKPyV serology
Pretransplant sera were available for serology analysis from 31 (67%) and post-transplant sera from 40 (87%) patients. Of the pretransplant sera, 13 patients were BKPyV-seronegative (42%) and 18 pa- These patients showed comparable GFR with BKPyV-negative patients. All four of them had Csa + Aza + MP as the baseline IS.
| Post-transplant BK viremia
During the study, nine patients developed BKPyV DNAemia as detected during routine screening samples. In 7 of these 9 patients, the first sample was taken 1 month after KT and was negative in all cases.
The 3-month sample was taken in all nine patients and was positive in seven. The last two patients developed viremia at 6 months. The median peak viral load of 7700 (range: 1035-189 000) copies/mL was detected at 4 months (range: 3-8) post-transplant. All the patients had positive BKPyV PCR in at least two samples. Three patients had high viral load BK viremia, with the viral load of 21 700, 23 300, and 189 000 copies/mL, and five patients had a peak load of >7000 copies/mL. Recipients under the age of 5 years showed a frequency of BK viremia similar to older children (17% vs. 23%, P = 0.718). Donor type was also comparable between patients with and without BK viremia (P = 0.881). IS was based on Tacro in 3 of 9 (33%) patients with viremia compared to 19% in non-viremic patients (P = 0.384).
Three of the 9 patients (33%) with BKPyV DNAemia had totally six episodes of Grade 1 acute rejections and 3 had borderline findings (Table 2) , which is more than observed in non-viremic patients (12%).
| BK viremia and graft function
At 3 months post-KT, six patients with early BK viremia (>400 copies/mL) showed significantly decreased GFR compared Values are number of patients (%), median (range), or mean ± SD.
TA B L E 2 Demographic data of 9 KT recipients with BK viremia Table 3 ). Also, creatinine levels were significantly higher in patients with viremia at 3 months (90.1 vs.
61, P = 0.032) and showed similar tendencies at 6 months (72 vs. 66, P = 0.268) and 12 months (98 vs. 66, P = 0.107) post-KT.
One of the six patients had acute rejection before the development of BKPyV DNAemia. Five of the six patients were on CsA at 3 months, and two had high trough levels (395 and 441 mg/L).
One patient was using Tacro and had appropriate drug level (8.0 mg/L). GFR and plasma creatinine values are demonstrated in relation to BK viremia in Figure 1 , and long-term graft function presented in Table 3 . 
| BKPyV and DSA
| Post-transplant PyVAN
Biopsy-proven PyVAN developed in three patients (6.5%) at 4, 10, and 11 months post-KT. One patient presented first with BK viremia and SV40 staining remained negative, but BKPyV DNA could be extracted from biopsy. Therapeutic reduction in IS was followed by a clear response as BKPyV DNA levels decreased successfully. In one case, the graft loss occurred later and was associated with ABMR.
| D ISCUSS I ON
Our study provides the first comprehensive data on BKPyV replica- Serological analysis assigns patients at the highest risk providing additional data for the early screening of BKPyV to support the diagnosis. For two-thirds of our patients, pretransplant sera were available indicating that 41% had very low or no BKPyV-specific IgG antibodies. CNF children who had severe hypogammaglobulinemia during infancy were clearly vulnerable to renal polyomavirus infection. After bilateral nephrectomy, which was performed a few months before transplantation, IgG levels normalized but many (72%) of the CNF children remained negative for BKPyV-specific IgG antibodies, which speaks for weak antibody response during the ne-
Several studies have demonstrated that absent or low BKPyVspecific antibody levels in KT recipients are associated with BKPyV replication both in pediatric and adult patients. Interestingly, one patient with early BK viremia and relative low peak viral load plasma (1035 copies/mL) in plasma showed BKPyV DNA in biopsy, possibly as a sign of donor-derived transmission.
Decreased GFR has been reported in patients with BK viremia alone or with BKVAN, 30, 32 and the significance of post-tranplant de novo DSAs in late ABMR is well emphasized.
33
In this study, two grafts were eventually lost due to ABMR with C4d positivity and DSAs. Both patients were adolescents at the time of operation, received HLA mismatched (≥4) kidneys. Viral DNA demonstrated by PCR in the biopsies confirmed the presence of polyomavirus in the kidney of both patients. Both responded well to the reduction in IS but developed ABMR later. Despite extensive ABMR treatment, these grafts were lost at 2-3 years after KT.
Antimetabolite was switched from AZA to MMF in both cases, and the maintenance IS was based on Tacro.
The use of Tacro associates with increased risk of BKPyV viremia at 6 and 12 months post-KT when compared to the use of CsA, as described in a prospective, randomized study demonstrating noninferiority with respect to immunological potency, biopsy-proven acute rejection, and graft loss. renal allograft involvement. A potential limitation of our study is the use of 4 log 10 copies/mL and 7 log 10 copies/mL in plasma and urine, TA B L E 3 Demographic data of patients with and without BK viremia org/index.php?pageId=3&pageVersion=EN).
In conclusion, BKPyV viremia is commonly detected in pediatric KT recipients in Finland at rates of 20%. Post-transplant BKPyV viremia occurred early (3-6 months post-KT) after transplantation and may contribute to the progression of chronic allograft injury. Low or absent BKPyV-specific antibody levels were seen before KT in 42% of tested patients, but were not predictive of poor outcome. The optimal management strategy remains undefined as to whether or not the calcineurin inhibitor, the antimetabolite, or both should be reduced in a stepwise fashion, 10, 35 as well as the potential role of ABMR occurring subsequent to this manoeuver. Since the sample size of this study is limiting the strength of the conclusions, larger cohort and registry studies are needed to address these important questions in the longer term.
CO N FLI C T O F I NTE R E S T S
The authors declare no conflict of interests.
AUTH O R CO NTR I B UTI O N
JM: collected and analyzed the data, performed research, and contributed to manuscript preparation; IL: designed the study, collected data, and contributed to manuscript preparation; MW: performed laboratory analyses; FW: performed laboratory analyses and contributed to manuscript preparation; EA and LM: performed PCR analyses; JL: collected data and contributed to manuscript preparation; HHH: designed the study, directed laboratory analyses, and contributed to manuscript preparation; HJ: designed the study and contributed to manuscript preparation.
F I G U R E 1 Continued
O RCI D
Jenni Miettinen http://orcid.org/0000-0003-4141-4878
